title: Text message content preferences to improve buprenorphine maintenance treatment in primary care.
abstract: Few studies have evaluated text message content preferences to support evidence-based treatment approaches for opioid use disorders, and none in primary care office-based buprenorphine treatment settings. This study assessed the acceptability and preferences for a tailored text message intervention in support of core office-based buprenorphine treatment medical management components (e.g., treatment adherence, encouraging abstinence, 12-step group participation, motivational interviewing, and patient-provider communication as needed). There were 97 patients enrolled in a safety net office-based buprenorphine treatment program who completed a 24-item survey instrument that consisted of multiple-choice responses, 7-point Likert-type scales, binomial "Yes/No" questions, and open-ended responses. The sample was predominately male (81%), had an average age of 46 years, and was diverse (64% ethnic/racial minorities); 56% lacked stable employment. Respondents were interested in receiving text message appointment reminders (90%), information pertaining to their buprenorphine treatment (76%), supportive content (70%), and messages to reduce the risk of relapse (88%). Participants preferred to receive relapse prevention text messages during all phases of treatment: immediately after induction into buprenorphine treatment (81%), a "few months" into treatment (57%), and after discontinuing buprenorphine treatment (72%). Respondents also expressed interest in text message content enhancing self-efficacy, social support, and frequent provider communication to facilitate unobserved "home" induction with buprenorphine. Older participants were significantly less receptive to receiving text message appointment reminders; however, they were as interested in receiving supportive, informational, and relapse prevention components compared to younger respondents. Implications for integrating a text message support system in office-based buprenorphine treatment are discussed.
authors.affiliation: a Department of Population Health , New York University School of Medicine , New York , New York , USA.|b Division of General Internal Medicine, New York University School of Medicine , New York , New York , USA.
authors.forename: Babak
authors.initials: B
authors.lastname: Tofighi
authors.affiliation: b Division of General Internal Medicine, New York University School of Medicine , New York , New York , USA.
authors.forename: Ellie
authors.initials: E
authors.lastname: Grossman
authors.affiliation: a Department of Population Health , New York University School of Medicine , New York , New York , USA.
authors.forename: Sewit
authors.initials: S
authors.lastname: Bereket
authors.affiliation: a Department of Population Health , New York University School of Medicine , New York , New York , USA.|b Division of General Internal Medicine, New York University School of Medicine , New York , New York , USA.
authors.forename: Joshua
authors.initials: J
authors.lastname: D Lee
mesh_terms: D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058850:Opiate Substitution Treatment / Q000379:methods*; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000523:psychology*; D057240:Patient Preference / Q000523:psychology*; D011320:Primary Health Care / Q000379:methods*; D017216:Telemedicine / Q000379:methods*; D060145:Text Messaging
chemical_list: D002047:Buprenorphine
keywords: Buprenorphine; mHealth; opioid dependence; text messaging